Epigenetic modifications have been well documented in autoimmune diseases. MicroRNAs (miRNAs), in particular, have long intrigued scientists in the field of autoimmunity. Owing to its central role in the development of the immune system, microRNA-155 (miR-155) is deeply involved in systemic lupus erythematosus (SLE). Despite the advancements made in treating SLE, the disease still remains incurable. Therefore, recent attention has been drawn to the manipulation of epigenetics in the development of curative treatments. In fact, it is a widely held view that miRNA-targeted therapy is a new glimmer of hope in the treatment of autoimmune diseases. However, the duplicity of miRNAs should not be overlooked. A single miRNA can target several mRNAs, and some mRNAs may possess opposing functions. In this review, we highlight the role of miR-155 as a biomarker and review its functions in SLE patients and animal models while discussing possible reasons behind inconsistencies across studies.

中文翻译：

---

SLE 中 miR-155 的奇特病例

表观遗传修饰已在自身免疫性疾病中得到充分证明。特别是 MicroRNA (miRNA)，长期以来一直吸引着自身免疫领域的科学家。由于其在免疫系统发育中的核心作用，microRNA-155 (miR-155) 与系统性红斑狼疮 (SLE) 密切相关。尽管在治疗 SLE 方面取得了进展，但这种疾病仍然无法治愈。因此，最近已经引起了人们对表观遗传学在治愈性治疗开发中的操纵的关注。事实上，人们普遍认为，miRNA靶向治疗是治疗自身免疫性疾病的一线希望。然而，不应忽视 miRNA 的重复性。单个 miRNA 可以靶向多个 mRNA，而一些 mRNA 可能具有相反的功能。在本次审查中，